Urolithiasis associated with topiramate
Int. braz. j. urol
;
30(1): 29-31, Jan.-Feb. 2004. ilus
Article
in English
| LILACS
| ID: lil-359781
RESUMO
OBJECTIVE:
Topiramate is a sulfamate-substituted monosaccharide anticonvulsant used as adjunctive therapy for intractable refractory seizures. It is report a case of topiramate-induced urolithiasis. CASE REPORT A 35-year-old man presented with acute, right-sided, colicky flank pain. He denied hematuria or dysuria. He was in use of phenytoin, risperidone, phenobarbital, and topiramate. The total daily dose of topiramate was 375 mg. A CT scan showed a 7 x 1 mm curvilinear density at the right ureterovesical junction with proximal hydrouretronephrosis. He was managed with rigid ureteroscopic stone extraction and the calculus metabolic analysis revealed the stone was composed of carbonate apatite (70 percent), calcium oxalate dihydrate (20 percent), and calcium oxalate monohydrate (10 percent).COMMENTS:
The present case typifies many features of topiramate-induced urolithiasis. Those who care for patients with urinary stone disease should be aware of this association.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Urinary Calculi
/
Fructose
/
Anticonvulsants
Type of study:
Etiology study
/
Risk factors
Limits:
Adult
/
Humans
/
Male
Language:
English
Journal:
Int. braz. j. urol
Journal subject:
Urology
Year:
2004
Type:
Article
Affiliation country:
United States
Institution/Affiliation country:
Duke University Medical Center/US
/
Northwestern University Medical School/US
Similar
MEDLINE
...
LILACS
LIS